Zealand Nabs Novo Nordisk To Save Zegalogue Launch
Boosts Turnaround At Troubled Danish Firm
Executive Summary
US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.
You may also be interested in...
Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial
Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.
Zealand Eyes Opportunities In Burgeoning Obesity Market
Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.